{"id":75,"date":"2020-04-21T12:46:21","date_gmt":"2020-04-21T12:46:21","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=75"},"modified":"2020-05-12T05:43:48","modified_gmt":"2020-05-12T05:43:48","slug":"18-march-2020-lopinavirritonavir-early-clinical-outcomes","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/18-march-2020-lopinavirritonavir-early-clinical-outcomes\/","title":{"rendered":"(18 March 2020) Lopinavir+Ritonavir- Early clinical outcomes"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\">Lopinavir+ Ritonavir- Secondary outcomes of study show some benefits<\/p>\n<p class=\"\">https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2001282<\/p>\n<p class=\"\">Cao et al. carried out a randomized, controlled, open-label trial for lopinavir\u2013ritonavir<br \/>\n(ritonavir helps to stabilize lopinavir) in 199 hospitalized patients with severe COVID-19, of whom 99 were assigned to the treatment group, and 100 received the standard of care. The authors found no benefit of lopinavir\u2013ritonavir time to clinical improvement beyond the standard of care, although lopinavir\u2013ritonavir was found to have benefit for some secondary endpoints, the safety of the treatment was confirmed, and future trials will verify the results.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Lopinavir+ Ritonavir- Secondary outcomes of study show some benefits https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2001282 Cao et al. carried out a randomized, controlled, open-label trial for lopinavir\u2013ritonavir (ritonavir helps to stabilize lopinavir) in 199 hospitalized patients with severe COVID-19, of whom 99 were assigned to&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/18-march-2020-lopinavirritonavir-early-clinical-outcomes\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(18 March 2020) Lopinavir+Ritonavir- Early clinical outcomes&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,12],"tags":[41],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/75"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=75"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/75\/revisions"}],"predecessor-version":[{"id":76,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/75\/revisions\/76"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=75"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=75"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=75"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}